Patents by Inventor Hiroyuki Tsunoda
Hiroyuki Tsunoda has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20250101118Abstract: The present invention provides pharmaceutical compositions comprising second-generation molecules that are superior than TOCILIZUMAB, by altering the amino acid sequences of the variable and constant regions of TOCILIZUMAB, which is a humanized anti-IL-6 receptor IgG1 antibody, to enhance the antigen-neutralizing ability and increase the pharmacokinetics, so that the therapeutic effect is exerted with a less frequency of administration, and the immunogenicity, safety and physicochemical properties (stability and homogeneity) are improved. The present invention also provides methods for producing these pharmaceutical compositions. The present inventors have successfully generated second-generation molecules that are superior to TOCILIZUMAB by appropriately combining amino acid sequence alterations in the CDR domains, variable regions, and constant regions.Type: ApplicationFiled: December 10, 2024Publication date: March 27, 2025Applicant: Chugai Seiyaku Kabushiki KaishaInventors: Tomoyuki Igawa, Shinya Ishii, Atsuhiko Maeda, Mika Sakurai, Tetsuo Kojima, Tatsuhiko Tachibana, Hirotake Shiraiwa, Hiroyuki Tsunoda, Yoshinobu Higuchi
-
Patent number: 12251676Abstract: A jig for inserting a packing into a flow passage of a reactor extending in one direction or for removing the packing from the flow passage, includes: a pair of strip portions extending in parallel with each other, having a length longer than the flow passage; and link portions arranged in an extending direction of the pair of strip portions, linking the pair of strip portions and having lengths with which the pair of strip portions sandwich the packing therebetween.Type: GrantFiled: February 28, 2022Date of Patent: March 18, 2025Assignee: IHI CorporationInventors: Yusuke Takeuchi, Akihisa Yano, Shunji Miyajima, Shigeki Sakakura, Taiga Yamamoto, Takuya Yoshinoya, Hiroyuki Kamata, Daisuke Tsunoda, Nobuyuki Honma
-
Patent number: 12253316Abstract: A heat exchange structure includes: two flow channels stacked in a stacking direction (Y direction) and thermally coupled to each other; and a fin structure detachably installed in at least one flow channel of the two flow channels. The fin structure includes fins arranged in a longitudinal direction (Z direction) of the at least one flow channel in which the fin structure is installed, the fins configured to form openings alternately arranged along the at least one flow channel on one side and the other side of the at least one flow channel in a width direction (X direction).Type: GrantFiled: December 22, 2022Date of Patent: March 18, 2025Assignee: IHI CORPORATIONInventors: Hiroyuki Kamata, Shigeki Sakakura, Nobuyuki Honma, Akihisa Yano, Taiga Yamamoto, Yusuke Takeuchi, Takuya Yoshinoya, Takuya Hashimoto, Daisuke Tsunoda
-
Publication number: 20250011443Abstract: The present inventors provide methods for modifying the isoelectric point of an antibody while retaining its antigen-binding activity, comprising modifying the charge of at least one exposable amino acid residue on the surface of the complementarity determining region (CDR). The present invention also provides methods for purifying multispecific antibodies, comprising modifying isoelectric point, and methods for improving the plasma pharmacokinetics of antibodies, comprising modifying isoelectric point. The present invention further provides antibodies with a modified isoelectric point, pharmaceutical compositions comprising the antibodies as an active ingredient, and methods for producing the antibodies and compositions.Type: ApplicationFiled: September 12, 2024Publication date: January 9, 2025Applicant: Chugai Seiyaku Kabushiki KaishaInventors: Tomoyuki Igawa, Hiroyuki Tsunoda, Tatsuhiko Tachibana, Taichi Kuramochi
-
Patent number: 12122840Abstract: The present inventors provide methods for modifying the isoelectric point of an antibody while retaining its antigen-binding activity, comprising modifying the charge of at least one exposable amino acid residue on the surface of the complementarity determining region (CDR). The present invention also provides methods for purifying multispecific antibodies, comprising modifying isoelectric point, and methods for improving the plasma pharmacokinetics of antibodies, comprising modifying isoelectric point. The present invention further provides antibodies with a modified isoelectric point, pharmaceutical compositions comprising the antibodies as an active ingredient, and methods for producing the antibodies and compositions.Type: GrantFiled: January 29, 2024Date of Patent: October 22, 2024Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Tomoyuki Igawa, Hiroyuki Tsunoda, Tatsuhiko Tachibana, Taichi Kuramochi
-
Patent number: 12116414Abstract: The present inventors provide methods for modifying the isoelectric point of an antibody while retaining its antigen-binding activity, comprising modifying the charge of at least one exposable amino acid residue on the surface of the complementarity determining region (CDR). The present invention also provides methods for purifying multispecific antibodies, comprising modifying isoelectric point, and methods for improving the plasma pharmacokinetics of antibodies, comprising modifying isoelectric point. The present invention further provides antibodies with a modified isoelectric point, pharmaceutical compositions comprising the antibodies as an active ingredient, and methods for producing the antibodies and compositions.Type: GrantFiled: February 5, 2024Date of Patent: October 15, 2024Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Tomoyuki Igawa, Hiroyuki Tsunoda, Tatsuhiko Tachibana, Taichi Kuramochi
-
Publication number: 20240301075Abstract: The present invention provides pharmaceutical compositions comprising second-generation molecules that are superior than TOCILIZUMAB, by altering the amino acid sequences of the variable and constant regions of TOCILIZUMAB, which is a humanized anti-IL-6 receptor IgG1 antibody, to enhance the antigen-neutralizing ability and increase the pharmacokinetics, so that the therapeutic effect is exerted with a less frequency of administration, and the immunogenicity, safety and physicochemical properties (stability and homogeneity) are improved. The present invention also provides methods for producing these pharmaceutical compositions. The present inventors have successfully generated second-generation molecules that are superior to TOCILIZUMAB by appropriately combining amino acid sequence alterations in the CDR domains, variable regions, and constant regions.Type: ApplicationFiled: May 1, 2024Publication date: September 12, 2024Applicant: Chugai Seiyaku Kabushiki KaishaInventors: Tomoyuki Igawa, Shinya Ishii, Atsuhiko Maeda, Mika Sakurai, Tetsuo Kojima, Tatsuhiko Tachibana, Hirotake Shiraiwa, Hiroyuki Tsunoda, Yoshinobu Higuchi
-
Publication number: 20240294653Abstract: The present inventors successfully obtained anti-NR10 antibodies having an effective neutralizing activity against NR10. The anti-NR10 antibodies provided by the present invention are useful as, for example, pharmaceuticals for treating or preventing inflammatory diseases.Type: ApplicationFiled: May 13, 2024Publication date: September 5, 2024Applicant: Chugai Seiyaku Kabushiki KaishaInventors: Taichi Kuramochi, Keiko Kasutani, Souhei Ohyama, Hiroyuki Tsunoda, Tomoyuki Igawa, Tatsuhiko Tachibana, Hirotake Shiraiwa, Keiko Esaki
-
Publication number: 20240239906Abstract: The present inventors provide methods for modifying the isoelectric point of an antibody while retaining its antigen-binding activity, comprising modifying the charge of at least one exposable amino acid residue on the surface of the complementarity determining region (CDR). The present invention also provides methods for purifying multispecific antibodies, comprising modifying isoelectric point, and methods for improving the plasma pharmacokinetics of antibodies, comprising modifying isoelectric point. The present invention further provides antibodies with a modified isoelectric point, pharmaceutical compositions comprising the antibodies as an active ingredient, and methods for producing the antibodies and compositions.Type: ApplicationFiled: February 5, 2024Publication date: July 18, 2024Applicant: Chugai Seiyaku Kabushiki KaishaInventors: Tomoyuki Igawa, Hiroyuki Tsunoda, Tatsuhiko Tachibana, Taichi ` Kuramochi
-
Publication number: 20240190976Abstract: The present inventors provide methods for modifying the isoelectric point of an antibody while retaining its antigen-binding activity, comprising modifying the charge of at least one exposable amino acid residue on the surface of the complementarity determining region (CDR). The present invention also provides methods for purifying multispecific antibodies, comprising modifying isoelectric point, and methods for improving the plasma pharmacokinetics of antibodies, comprising modifying isoelectric point. The present invention further provides antibodies with a modified isoelectric point, pharmaceutical compositions comprising the antibodies as an active ingredient, and methods for producing the antibodies and compositions.Type: ApplicationFiled: January 29, 2024Publication date: June 13, 2024Applicant: Chugai Seiyaku Kabushiki KaishaInventors: Tomoyuki Igawa, Hiroyuki Tsunoda, Tatsuhiko Tachibana, Taichi Kuramochi
-
Publication number: 20240010738Abstract: The present invention provides pharmaceutical compositions comprising second-generation molecules that are superior than TOCILIZUMAB, by altering the amino acid sequences of the variable and constant regions of TOCILIZUMAB, which is a humanized anti-IL-6 receptor IgG1 antibody, to enhance the antigen-neutralizing ability and increase the pharmacokinetics, so that the therapeutic effect is exerted with a less frequency of administration, and the immunogenicity, safety and physicochemical properties (stability and homogeneity) are improved. The present invention also provides methods for producing these pharmaceutical compositions. The present inventors have successfully generated second-generation molecules that are superior to TOCILIZUMAB by appropriately combining amino acid sequence alterations in the CDR domains, variable regions, and constant regions.Type: ApplicationFiled: September 11, 2023Publication date: January 11, 2024Applicant: Chugai Seiyaku Kabushiki KaishaInventors: Tomoyuki Igawa, Shinya Ishii, Atsuhiko Maeda, Mika Sakurai, Tetsuo Kojima, Tatsuhiko Tachibana, Hirotake Shiraiwa, Hiroyuki Tsunoda, Yoshinobu Higuchi
-
Publication number: 20230183363Abstract: The present inventors successfully obtained anti-NR10 antibodies having an effective neutralizing activity against NR10. The anti-NR10 antibodies provided by the present invention are useful as, for example, pharmaceuticals for treating or preventing inflammatory diseases.Type: ApplicationFiled: October 28, 2022Publication date: June 15, 2023Applicant: Chugai Seiyaku Kabushiki KaishaInventors: Taichi Kuramochi, Keiko Kasutani, Souhei Ohyama, Hiroyuki Tsunoda, Tomoyuki Igawa, Tatsuhiko Tachibana, Hirotake Shiraiwa, Keiko Esaki
-
Publication number: 20230159648Abstract: The present invention provides pharmaceutical compositions comprising second-generation molecules that are superior than TOCILIZUMAB, by altering the amino acid sequences of the variable and constant regions of TOCILIZUMAB, which is a humanized anti-IL-6 receptor IgG1 antibody, to enhance the antigen-neutralizing ability and increase the pharmacokinetics, so that the therapeutic effect is exerted with a less frequency of administration, and the immunogenicity, safety and physicochemical properties (stability and homogeneity) are improved. The present invention also provides methods for producing these pharmaceutical compositions. The present inventors have successfully generated second-generation molecules that are superior to TOCILIZUMAB by appropriately combining amino acid sequence alterations in the CDR domains, variable regions, and constant regions.Type: ApplicationFiled: January 12, 2023Publication date: May 25, 2023Applicant: Chugai Seiyaku Kabushiki KaishaInventors: Tomoyuki Igawa, Shinya Ishii, Atsuhiko Maeda, Mika Sakurai, Tetsuo Kojima, Tatsuhiko Tachibana, Hirotake Shiraiwa, Hiroyuki Tsunoda, Yoshinobu Higuchi
-
Patent number: 11576969Abstract: Provided is a novel anti-Plexin-A1 agonist antibody that promotes dendritic cell contraction. Also provided is a pharmaceutical composition comprising such an antibody and a pharmaceutically acceptable carrier.Type: GrantFiled: May 8, 2020Date of Patent: February 14, 2023Assignees: Osaka University, Chugai Seiyaku Kabushiki KaishaInventors: Atsushi Kumanogoh, Ryusuke Omiya, Hiroyuki Tsunoda, Takeshi Baba, Sachiyo Suzuki, Yuri Teranishi
-
Publication number: 20220389105Abstract: The present inventors provide methods for modifying the isoelectric point of an antibody while retaining its antigen-binding activity, comprising modifying the charge of at least one exposable amino acid residue on the surface of the complementarity determining region (CDR). The present invention also provides methods for purifying multispecific antibodies, comprising modifying isoelectric point, and methods for improving the plasma pharmacokinetics of antibodies, comprising modifying isoelectric point. The present invention further provides antibodies with a modified isoelectric point, pharmaceutical compositions comprising the antibodies as an active ingredient, and methods for producing the antibodies and compositions.Type: ApplicationFiled: January 19, 2022Publication date: December 8, 2022Applicant: Chugai Seiyaku Kabushiki KaishaInventors: Tomoyuki Igawa, Hiroyuki Tsunoda, Tatsuhiko Tachibana, Taichi Kuramochi
-
Publication number: 20220306755Abstract: The present invention provides pharmaceutical compositions comprising second-generation molecules that are superior than TOCILIZUMAB, by altering the amino acid sequences of the variable and constant regions of TOCILIZUMAB, which is a humanized anti-IL-6 receptor IgG1 antibody, to enhance the antigen-neutralizing ability and increase the pharmacokinetics, so that the therapeutic effect is exerted with a less frequency of administration, and the immunogenicity, safety and physicochemical properties (stability and homogeneity) are improved. The present invention also provides methods for producing these pharmaceutical compositions. The present inventors have successfully generated second-generation molecules that are superior to TOCILIZUMAB by appropriately combining amino acid sequence alterations in the CDR domains, variable regions, and constant regions.Type: ApplicationFiled: June 1, 2022Publication date: September 29, 2022Applicant: Chugai Seiyaku Kabushiki KaishaInventors: Tomoyuki Igawa, Shinya Ishii, Atsuhiko Maeda, Mika Sakurai, Tetsuo Kojima, Tatsuhiko Tachibana, Hirotake Shiraiwa, Hiroyuki Tsunoda, Yoshinobu Higuchi
-
Publication number: 20220267822Abstract: In the course of the present invention, it was discovered that one could regulate association between polypeptides by modifying amino acid residues that form the interface during the association to amino acids carrying the same type of charge. In this context, the present invention enables efficient formation of heterologous molecules. For example, the present invention can be suitably applied to the preparation of bispecific antibodies.Type: ApplicationFiled: November 5, 2021Publication date: August 25, 2022Applicant: Chugai Seiyaku Kabushiki KaishaInventors: Tomoyuki Igawa, Hiroyuki Tsunoda
-
Patent number: 11359175Abstract: In an aspect, the present invention provides a structure, a structure-manufacturing method, a cell-sorting method, or the like. In an aspect, a structure (1) of the present invention is a structure including a first substrate (10) and a second substrate (20) disposed to face one side of the first substrate (10), in which the first substrate (10) has a plurality of depressions (11) which are open to the other side of the first substrate and each of which has a size that enables each of the depressions to capture one unit of a cell, at least some of the depressions (11) have communication holes (12) which communicate with one side and the other side of the first substrate and each of which has a size that enables secretions secreted from the cell to move through the communication holes, the second substrate (20) can include accumulation portions (13) in which the secretions moving through the communication holes (12) are accumulated, and the accumulation portions (13) can correspond to the depressions (11).Type: GrantFiled: September 26, 2016Date of Patent: June 14, 2022Assignees: TOKYO OHKA KOGYO CO., LTD., CHUGAI SEIYAKU KABUSHIKI KAISHAInventors: Takashi Ohsaka, Yasuo Suzuki, Toshiyuki Ogata, Takuya Noguchi, Noriyuki Takahashi, Takeshi Baba, Hiroyuki Tsunoda
-
Patent number: 11248053Abstract: The present inventors provide methods for modifying the isoelectric point of an antibody while retaining its antigen-binding activity, comprising modifying the charge of at least one exposable amino acid residue on the surface of the complementarity determining region (CDR). The present invention also provides methods for purifying multispecific antibodies, comprising modifying isoelectric point, and methods for improving the plasma pharmacokinetics of antibodies, comprising modifying isoelectric point. The present invention further provides antibodies with a modified isoelectric point, pharmaceutical compositions comprising the antibodies as an active ingredient, and methods for producing the antibodies and compositions.Type: GrantFiled: October 5, 2017Date of Patent: February 15, 2022Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Tomoyuki Igawa, Hiroyuki Tsunoda, Tatsuhiko Tachibana, Taichi Kuramochi
-
Publication number: 20220041741Abstract: The present invention provides pharmaceutical compositions comprising second-generation molecules that are superior than TOCILIZUMAB, by altering the amino acid sequences of the variable and constant regions of TOCILIZUMAB, which is a humanized anti-IL-6 receptor IgG1 antibody, to enhance the antigen-neutralizing ability and increase the pharmacokinetics, so that the therapeutic effect is exerted with a less frequency of administration, and the immunogenicity, safety and physicochemical properties (stability and homogeneity) are improved. The present invention also provides methods for producing these pharmaceutical compositions. The present inventors have successfully generated second-generation molecules that are superior to TOCILIZUMAB by appropriately combining amino acid sequence alterations in the CDR domains, variable regions, and constant regions.Type: ApplicationFiled: October 25, 2021Publication date: February 10, 2022Applicant: Chugai Seiyaku Kabushiki KaishaInventors: Tomoyuki Igawa, Shinya Ishii, Atsuhiko Maeda, Mika Sakurai, Tetsuo Kojima, Tatsuhiko Tachibana, Hirotake Shiraiwa, Hiroyuki Tsunoda, Yoshinobu Higuchi